Repligen (NASDAQ:RGEN) Issues Quarterly Earnings Results

Repligen (NASDAQ:RGEN - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09, Briefing.com reports. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. During the same quarter in the prior year, the business posted $0.23 EPS. The business's revenue was up 9.7% compared to the same quarter last year. Repligen updated its FY24 guidance to $1.50-1.58 EPS and its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Trading Up 1.3 %

NASDAQ RGEN traded up $1.88 on Wednesday, reaching $150.47. The stock had a trading volume of 1,073,620 shares, compared to its average volume of 659,834. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The firm has a fifty day moving average of $141.34 and a two-hundred day moving average of $144.87.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of recent analyst reports. Benchmark reiterated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Stephens reiterated an "overweight" rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Royal Bank of Canada reissued an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. UBS Group reduced their target price on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $190.25.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.